Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1

[1]  B. Cen,et al.  Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening , 2023, Frontiers in Oncology.

[2]  S. Chan,et al.  Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond , 2022, Current oncology.

[3]  J. Gallon,et al.  Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report , 2022, Communications Medicine.

[4]  N. Barlev,et al.  The Role of E3 Ligase Pirh2 in Disease , 2022, Cells.

[5]  L. di Tommaso,et al.  A clinical and pathological update on hepatocellular carcinoma , 2022, Journal of liver cancer.

[6]  Ji-Young Kim,et al.  Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer , 2022, Scientific Reports.

[7]  J. Sung,et al.  PROX1, a Key Mediator of the Anti-Proliferative Effect of Rapamycin on Hepatocellular Carcinoma Cells , 2022, Cells.

[8]  Jinyuan Li,et al.  Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis , 2022, BMC Complementary Medicine and Therapies.

[9]  V. Cristini,et al.  Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.

[10]  Bo Zhou,et al.  Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials , 2021, Frontiers in Oncology.

[11]  C. Xie,et al.  Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review) , 2021, International journal of oncology.

[12]  R. Nagarkar,et al.  Hepatocellular carcinoma with uncommon sites of metastasis: a rare case report , 2021, Egyptian Journal of Radiology and Nuclear Medicine.

[13]  R. Gónzalez-Gónzalez,et al.  Epithelial–Mesenchymal Transition Associated with Head and Neck Squamous Cell Carcinomas: A Review , 2021, Cancers.

[14]  Nicolò Riggi,et al.  TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth , 2021, Communications Biology.

[15]  Xing-Xing He,et al.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets , 2021, Journal of Experimental & Clinical Cancer Research.

[16]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. , 2021, The oncologist.

[17]  Sayeon Cho,et al.  The Post-Translational Regulation of Epithelial–Mesenchymal Transition-Inducing Transcription Factors in Cancer Metastasis , 2021, International journal of molecular sciences.

[18]  Qin Chen,et al.  TWIST1 expression and clinical significance in type I endometrial cancer and premalignant lesions , 2020, Medicine.

[19]  M. Abbaszadegan,et al.  TWIST1 upregulates matrix metalloproteinase (MMP) gene family in esophageal squamous carcinoma cells. , 2020, Gene expression patterns : GEP.

[20]  Chao Wei,et al.  TRIP suppresses cell proliferation and invasion in choroidal melanoma via promoting the proteasomal degradation of Twist1 , 2020, FEBS letters.

[21]  Qingquan Liu,et al.  MYB Proto-oncogene-like 1-TWIST1 Axis Promotes Growth and Metastasis of Hepatocellular Carcinoma Cells , 2020, Molecular therapy oncolytics.

[22]  R. Sabarinathan,et al.  Twist1 induces chromosomal instability (CIN) in colorectal cancer cells , 2020, Human molecular genetics.

[23]  I. Georgakopoulos-Soares,et al.  EMT Factors and Metabolic Pathways in Cancer , 2020, Frontiers in Oncology.

[24]  M. Fares,et al.  Molecular principles of metastasis: a hallmark of cancer revisited , 2020, Signal Transduction and Targeted Therapy.

[25]  Pengwei Zhao,et al.  SRC-1 and Twist1 are prognostic indicators of liver cancer and are associated with cell viability, invasion, migration and epithelial-mesenchymal transformation of hepatocellular carcinoma cells , 2020, Translational cancer research.

[26]  U. Yadav,et al.  MMP-2 and MMP-9 mediate cigarette smoke extract-induced epithelial-mesenchymal transition in airway epithelial cells via EGFR/Akt/GSK3β/β-catenin pathway: Amelioration by fisetin. , 2019, Chemico-biological interactions.

[27]  M. Neagu,et al.  The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma , 2019, Analytical cellular pathology.

[28]  Kefei Yuan,et al.  TXNDC12 promotes EMT and metastasis of hepatocellular carcinoma cells via activation of β-catenin , 2019, Cell Death & Differentiation.

[29]  G. Sethi,et al.  The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges , 2019, Cells.

[30]  Sun-Mi Park,et al.  p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation that is Required for GSK3β-βTrCP-Induced Snail Degradation. , 2019, Cancer research.

[31]  Huiyin Lan,et al.  Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications , 2019, Journal of Hematology & Oncology.

[32]  V. Díaz,et al.  Snail1: A Transcriptional Factor Controlled at Multiple Levels , 2019, Journal of clinical medicine.

[33]  S. Ziegler,et al.  Dual-targeted NIS polyplexes—a theranostic strategy toward tumors with heterogeneous receptor expression , 2019, Gene Therapy.

[34]  M. Rath,et al.  In Vitro Effect of Cytokines, Inducers, and Inhibitors on the Secretion of MMP-2 and MMP-9 in Hepatocarcinoma Cell Line SK-Hep-1 , 2019, Integrative Cancer Therapies.

[35]  Wei Cheng,et al.  Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. , 2018, Oncology letters.

[36]  Junhong Li,et al.  Identification of potential therapeutic targets in hepatocellular carcinoma using an integrated bioinformatics approach , 2018, Translational Cancer Research.

[37]  A. Pandey,et al.  Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers , 2018, Current chemical genomics and translational medicine.

[38]  K. Tam,et al.  Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes , 2018, International journal of biological sciences.

[39]  Sanqiang Li,et al.  Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis , 2017, PloS one.

[40]  K. Shah,et al.  The Aurora-A–Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma , 2017, Journal of Cell Science.

[41]  S. Powers,et al.  The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. , 2016, Molecular cell.

[42]  M. Mandalà,et al.  AKT-ions with a TWIST between EMT and MET , 2016, Oncotarget.

[43]  P. Singh,et al.  Kinases inhibitors in lung cancer: From benchside to bedside. , 2016, Biochimica et biophysica acta.

[44]  A. Nielsen,et al.  The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. , 2016, Translational lung cancer research.

[45]  Hongyang Wang,et al.  A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression , 2015, Molecular Cancer.

[46]  Liwu Fu,et al.  Pelitinib (EKB‐569) targets the up‐regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer , 2015, British journal of pharmacology.

[47]  C. Hou,et al.  Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway , 2014, Molecular Cancer.

[48]  D. Medici,et al.  Signaling mechanisms of the epithelial-mesenchymal transition , 2014, Science Signaling.

[49]  P. Sáha,et al.  HaCaT Keratinocytes Response on Antimicrobial Atelocollagen Substrates: Extent of Cytotoxicity, Cell Viability and Proliferation , 2014, Journal of functional biomaterials.

[50]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[51]  P. ten Dijke,et al.  Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. , 2013, Trends in biochemical sciences.

[52]  X. Qiu,et al.  Prognostic Significance of Twist and N-Cadherin Expression in NSCLC , 2013, PloS one.

[53]  C. Park,et al.  CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection , 2013, Korean journal of pathology.

[54]  H. Lim,et al.  Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways , 2011, Journal of Korean medical science.

[55]  Tao He,et al.  Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms , 2011, Cell Research.

[56]  S. Choo,et al.  Targeted Therapy in Hepatocellular Carcinoma , 2011, International journal of hepatology.

[57]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[58]  C. Cadilla,et al.  Redundant or separate entities?—roles of Twist1 and Twist2 as molecular switches during gene transcription , 2010, Nucleic acids research.

[59]  B. Hemmings,et al.  PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage , 2010, Oncogene.

[60]  M. Waltham,et al.  Epithelial-to-Mesenchymal Transitions and Circulating Tumor Cells , 2010, Journal of Mammary Gland Biology and Neoplasia.

[61]  G. Yen,et al.  Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. , 2010, Journal of agricultural and food chemistry.

[62]  Bao-cun Sun,et al.  Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry , 2010, Hepatology.

[63]  S. Chiou,et al.  Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma , 2009, Hepatology.

[64]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[65]  Sheung Tat Fan,et al.  Twist Overexpression Correlates with Hepatocellular Carcinoma Metastasis through Induction of Epithelial-Mesenchymal Transition , 2006, Clinical Cancer Research.

[66]  S. Kropf,et al.  Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas , 2005, Clinical Cancer Research.

[67]  L. Ellis.  Epidermal growth factor receptor in tumor angiogenesis. , 2004, Hematology/oncology clinics of North America.

[68]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[69]  Shujun Liu,et al.  Screening and validation of prognostic indicator genes in the progression of HBV related hepatocellular carcinoma , 2023, Biomedical Technology.

[70]  K. Smalley,et al.  Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines. , 2010, Methods in enzymology.